#Praluent
LightNews LightNews
scientistswanda.bsky.social
Praluent is a great example of how blocking a single protein can reshape cholesterol metabolism. By inhibiting PCSK9, it preserves LDL receptors on the liver and dramatically increases LDL clearance. Learn how this mechanism works in my new science video!
youtu.be/L0GS8L3mZWA
How does Praluent (Alirocumab) Work to Reduce Cholesterol?
YouTube video by Dr. Rob Swanda
youtu.be
September 15, 2026 at 9:09 PM
dralo.bsky.social
What is a PCSK9 inhibitor? #pcsk9 #Repatha #Praluent #inclisarin #cholesterol
August 9, 2026 at 1:36 PM
nicconova.bsky.social
Jag har praluent och även med den kickar högkostnadsskyddet in vid första uttaget. Bra grej ändå det där skyddet
August 9, 2026 at 8:13 AM
nicconova.bsky.social
Haha har du praluent månne?
August 6, 2026 at 1:56 PM
peoplespharmacy.bsky.social
Will Praluent, Repatha or Lipfendra Work If You Can’t Stand a Statin? www.peoplespharmacy.com/articles/wil... via @peoplespharmacy

#Praluent #Repatha #Lipfendra #statins #cholesterol #health
Will Praluent, Repatha or Lipfendra Work If You Can’t Stand a Statin?
What can you do when your doctor insists you must take a statin but you experience unbearable muscle pain and weakness. Praluent or Repatha?
www.peoplespharmacy.com
July 30, 2026 at 3:54 PM
yourdigitalbrain.bsky.social
Until now, the only approved PCSK9 inhibitors were bi-monthly injections like Repatha and Praluent, priced up to $600 per month , creating an access barrier that left millions of high cardiovascular risk patients without adequate treatment.
Lipfendra (enlicitide): Merck launches the first oral PCSK9 inhibitor with 59% LDL reduction - Sinaptica
The United States Food and Drug Administration (FDA) approved on July 16, 2026 a groundbreaking cardiovascular treatment: Lipfendra (enlicitide) from Merck, the
sinapti.ca
July 19, 2026 at 7:15 AM
health.hivewire.news
Merck wins US approval for first PCSK9 pill #health #medicine #news
Merck wins US approval for first PCSK9 pill
The FDA approved Merck's LIPFENDRA (enlicitide) as the first once-daily oral PCSK9 inhibitor to lower LDL-C in adults with hypercholesterolemia. In trials, it reduced LDL-C by up to 59% versus placebo, offering a new option beyond statins and injectable rivals like Repatha and Praluent.
hivewire.news
July 16, 2026 at 12:00 PM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01088045.jpg
#epsteinweb #efta01088045
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01088033 | EFTA01088045 Regeneron (REGN) I Buy I B-1-9 I $525 REGN. a perennial MI powerhouse, currently only markets Eylea for wet macular degeneration and Arcalyst for cryopyrin-associated periodic syndroms (CAPS). However, it also books revenues for Praluent (alirocumab) from its collaboration with Sanofi and ex-US revenues for Eylea from its collaboration with Bayer. With only one marketed product, it would seem that REGN's NPV would be very pipeline heavy, but with a strong base of Eylea sales. REGN's value mainly comes from its products. We view this as a very attractive opportunity, given the protection it would have against a market downturn from its BB and the growth opportunity from its late stage pipeline. In addition, REGN is screening cheap, compared to historical valuations. Note however, that as the third most overweight biotech relative to the S&P 500, repositioning remains a risk. Chart 17: REGN product and pipeline portfolio NPV S450 S400 5350 5300 S250 S200 5150 5100 - 5244 5244 REGN REGN wldupilumab and sarilumab S50 50 ■ Eylea ■ Praluent ■ Dupilumab ■ Sarikirnab ■ Net cash Pipeline Source Bole Mean !ovenGlobalResearch estimates NPV assumptions for marketed products Each valuation scenario above assumes Eylea and Praluent revenues through 2020. 514/sh net cash NPV and a 10.3% WACC. Eylea's $244/sh NPV assumes revenue growth to $4.0B peak sales in 2019. Praluent's $39/sh NPV assumes growth to 2020 sales of 51.0B. In this scenario, the BB accounts for 72% of REGN's total NPV, with the pipeline representing 5117/sh. Valuation with dupilumab and sarilumab factored in We incorporate dupilumab and sarilumab into our second scenario because of the clinical success they have shown in the late stages of development In this case, our analysis gives dupilumab for atopic dermatitis and asthma an NPV of 522/sh, assuming sales quickly grow to 51.8B in 2025. Our analysis also gives sarilumab for RA 57/sh NPV from the collaboration with Sanofi. Accounting for the potential approvals of dupilumab and sarilumab, REGN's BB represents 79% of its total NPV, with the pipeline offering $88/sh. Bank of Amenca "gra" Merrill Lynch Biotechnology 19 April 2016 13 EFTA01088045
May 9, 2026 at 1:33 AM
epsteinweb.bsky.social
EFTA01088037.jpg
#epsteinweb #efta01088037
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01088033 | EFTA01088037 Table 3: Company NPVs by drug /LINN $11 $21 $24 $15 BIIB Tecfidera $78 Interferon $40 Tysabri $23 Others $38 CELG Revlimid $49 ThatNIdaza St Pomal s $9 $5 GILD HCV $43 HIV $40 Others $5 Eylea $244 $244 Praluent $39 $39 Dupilumab Sarilumab REGN widup and sari $22 $7 ALXN ALXN w!compelition Solids S125 $65 Strenslq $25 $25 Kanuma SI8 SI8 Na la $13 $49 $6 SO $42 $120 $162 74% Net cash ($2) Pipeline $94 Total $177 Price $271 % base biz 65% ($9) $44 $63 $107 59% Net cash $4 Pipeline S8 Total $92 Price $99 % base biz 92% Net cash S14 S14 Pipeline 5117 $88 Total $297 $326 Price $414 $414 % base biz 72% 79% Net cash ($8) ($8) Pipeline ($4) $58 Total $160 $100 Price $155 $155 % base biz 103% 64% $2 $34 S52 S86 60% BAIRN Alduraz me S5 VRTX Kal d $15 $58 $3 S7 $76 $83 91% Jakall $37 Baricitinib $20 Net cash $1 Pipeline $19 Total $58 Price $77 % base biz 75% INCY Source Sof/WNW 4naltictateessych Banker Amenca 4"3" Merrill Lynch S3 $29 Biotechnology 19 April 2016 $ EFTA01088037
May 9, 2026 at 1:32 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA01088036.jpg
#epsteinweb #efta01088036
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA01088033 | EFTA01088036 Chart 7: S&P 500 Biotech industry: relative Price/Sales (1993-3/2016) Chart 8: S&P 500 Biotech industry: relative fwd. P/E (1993-3/2016) 12.00 i 3.00 10.00 2.50 8.00 2.00 6.00 A W 1.50 1.00 4.00 .1 0.50 2.00 93 95 97 99 01 03 —Relative P/S 05 07 93 09 11 13 15 95 97 99 01 03 05 —Relative Fwd PIE —Avg 07 09 11 13 15 -Avg SCUM FacrSet. Both.MemllLynchUS Equity & US Quant Strategy Sauce. Fac6et.BolA Mend Lynch US Equity & US Quant Strategy Table 2: S&P 500 Biotech - relative valuations vs. history (1992-3/2016) Implied upside (downside) Metric Current Avg. to get back to UT avg. Relative PG 2.6 2.0 -21% Relative NS 3.0 5.1 71% Relative Fed PI 0.7 1.3 78% Relative NOCE 1.1 1.9 74% Chart 9: Biotedt growth at a reasonable pike S&P 500 sectors and Health Care industries Fwd P;E vs. Consensus LTG (as of 3/31/16) 22x Life So Tools 21x Cons. Staplos• 8 Svcs 20x 19x HC Eqpt 8 • Coos. Disc. 18x Slehl. 17x Industrials • 18x Rharrna • 15x 14x Telecom Financials 13x C• Biotech) 12x 11x 0.0 2.0 4.0 8.0 8.0 10.0 12.0 14.0 16.0 18.0 20.0 Consensus Long-Tenn Growth Note based on aggregate %Suiten multiple miaow to S&P SOO milurie Source FacrSet. BOO .Memll Lynch US Equity & USQuaStrategy r. I Sauce. FaciSet.80% Mend Lynch US Equity & US Quant Strategy Valuations reflect mainly base businesses for most We reviewed the net present values (NPVs) for ALXN, AMGN, BIIB, BMRN, CELG. GILD, INCY, REGN, and VRTX — taking apart the base business (BB) vs pipeline contributions. Based on our analysis, the BBs for ALXN. AMGN, GILD. INCY, REGN, and VRTX reflect about 75%-100% of the current valuation with little premium from the pipeline. This should be viewed favorably in a nervous market and could protect against significant downside in a market downturn and offer upside if pipeline assets report favorable clinical data. Of these. AMGN, REGN. and VRTX will report later-stage clinical data in 2016 that could meaningfully drive shares higher, including Repatha outcomes data for AMGN, interim Praluent outcomes data for REGN. and VX661/Kalydeco and early triple combo data for VRTX. In addition to clinical read-outs on new indications for Saris, ALXN also has two product launches (Strensiq and Kanuma) that began late last year; we believe the long-term market opportunities for these are not reflected in the price. Not surprisingly. heavy weights BIIB, BMRN, and CELG screen lower with their BBs representing only 55%-65% of current valuations. We believe these are justified given the number of late-stage large trials each have underway that could significantly accelerate growth in the next few years. BIIB has Phase 3 aducanumab in Alzheimer's and Phase 3 anti-LINGO in multiple sclerosis data. BMRN has multiple catalysts over the next 12 months, including updates for BMN190 for Batten's disease. 30mcg data for BMN111 for achondroplasia, and preliminary data for BMN270 for Hemophilia A. CELG has the PDUFA date for Revlimid for patients with non-del-Sq myelodysplastic syndromes (MDS) on April 16 and Ozanimod data in 1H1 7. 4 Biotechnology 19 April 2016 ," Bankof America 40 Merrill Lynch EFTA01088036 Epstein Web iOS app on the App Store.
May 9, 2026 at 1:32 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA00850480.jpg
#epsteinweb #efta00850480
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA00850478 | EFTA00850480 ODYSSEY Program The ODYSSEY Phase 3 program is one of the most comprehensive clinical trial programs ever conducted for an investigational LDL cholesterol lowering therapy. The program includes 14 global Phase 3 trials evaluating more than 23,500 patients. The primary efficacy end point in all of the studies was the mean percent reduction from baseline in LDL cholesterol at week 24 compared to placebo (maximally tolerated statin therapy); all of the completed studies met their primary endpoint. A significantly higher proportion of patients achieved LDL cholesterol of less than 70 mg/I:IL in the Praluent group as compared to placebo at both week 12 and week 24. The ongoing ODYSSEY OUTCOMES trial will prospectively evaluate the cardiovascular benefits of Praluent in approximately 18.000 patients. Important Safety Information Do not use PRALUENT if you are allergic to alirocumab or to any of the ingredients in PRALUENT. Before you start using PRALUENT, tell your healthcare provider about all your medical conditions, including allergies, and if you are pregnant or plan to become pregnant or if you arc breastfeeding or plan to brcastfeed. Tell your healthcare provider or pharmacist about any prescription and over-the-counter medicines you are taking or plan to take, including natural or herbal remedies. PRALUENT can cause serious side effects, including allergic reactions that can be severe and require treatment in a hospital. Call your healthcare provider or go to the nearest hospital emergency room right away if you have any symptoms of an allergic reaction including a severe rash, redness, severe itching, a swollen fact or trouble breathing. The most common side effects of PRALUENT include: redness, itching. swelling, or painitendcmess at the injection site, symptoms of the common cold. and flu or flu-like symptoms. Tell your healthcare provider if you have any side effect that bothers you or that does not go away. Talk to your doctor about the right way to prepare and give yourself a PRALUENT injection and follow the "Instructions for Use" that comes with Pmluent. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit Ignmilda,govirm•dwatett or call I-800-FDA-1088Ca. Please click here for the full Prescribing Information. About Sanofi Sane!. an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sancti' has core strengths in the field of healthcare with seven growth platforms: diabetes solutions. human vaccines, innovative drugs. consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: Sal) and in New York (NYSE: SIX). please note The information contained in this communication is confidential. may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to jeevacation(a2gmaiLeon', and destroy this communication and all copies thereof. including all attachments. copyright -all rights reserved EFTA00850480
May 7, 2026 at 4:26 AM
epsteinweb.bsky.social
Parts 1-4/5 — EFTA00850479.jpg
#epsteinweb #efta00850479
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA00850478 | EFTA00850479 Most Popular Photo,: America's New Manufacturing Boomtowns (_barrel igiligg With A Thrillionaire Entrumgaggr MostPopular Harrel Rolling With A Thriffionaire Entrepreneur MostPopular Photos: The 10 Best And Worst States To Make A Living In 2015 clitmaldartump And The Occhtir Of American ('haracter—A Cautionary Ink Lending on I inket110 Donald "frump And The Recline Of American Character—A rautionsoath "We don't want the noise about these drugs to be pricer says Leonard Schleifer, the chief executive and founder of Regcncron. "We have to make sure that people get access to the dmg fora fair price if they're insured, for free if they're not insured, or at a discount if they're under-insured." Praluent's price is 46% higher than that forecast by Evercore ISI, an investment bank, and it is being approved for a larger group of patients than many Wall Street analysts expected following a meeting convened by the FDA to analyze the data on the drug. Some doctors argued its use should be restricted mainly to patients with FH. But Mark Schoencbaum, Evercore ISI's pharmaceutical analyst, says that investors were initially disappointed because they had hoped the FDA would green' ight the drug for an even broader group. Regencron shares were down 2.5% in afternoon trading before they were halted pending news. But doctors may prescribe the drug more widely than the label suggests. A survey of physicians published this morning by Geoffrey Forges, an biotechnology analyst at investment bank Sanford C. Bernstein. found that they would use the drug in 30% to 40% of patients who had already had heart attacks. He wrote that 2020 sales of Praluent could be as high as $4.8 billion. In the survey, doctors expressed a preference for Pralucnt. One advantage of Regencron's drug is that doctors will be able to start it at a lower, 75 milligram dose. Schleifer, who is a medical doctor and, incidentally, a billionaire thanks to his Regencron stake, says that the company expects that as many as 8 million people who don't have their cholesterol well-controlled could be candidates for Praluent. He emphasized. though. that until larger studies prove the drug prevents heart attacks and strokes patients should always choose statins first. It will have sales representatives a Insurance companies and pharmacy benefit managers. who help insurers and employers manage drug costs, arc going to do their best to restrict use of Pralucnt, though. Brennan, the CVS Caremark executive, says that he expects patients will need to have medical records documenting that they have already taken statins. Those not taking statins would need a blood test confirming that a statin caused elevations in muscle or liver enzymes. not just complaints that they were achy. "We're not trying to replace Matins." says Schliefer, the Regencron CEO. Most people who have muscle problems from statins do not have those elevated muscle enzymes, says Nissen, the Cleveland Clinic cardiologist, who is conducting a clinical trial Amgen and Pfizer. which is also developing a similar cholesterol drug. He says he has patients who are "desperate" to take a statin but who cannot tolerate it because of muscle pain but do not have elevated muscle enzymes. "Dehspite significant progress over the last decades, high cholesterol remains a leading concern in the U.S. and globally." said Olivier Brandicourt, MI., Chief Executive Officer, Semi& "Praluent demonstrates the power of the Sanofi and Regcncron alliance to deliver a first-in-class therapy in the U.S. for patients in need. Sandi has a strong cardiovascular heritage and dedication to these patients. and we look forward to working with other regulatory authorities to make Praluent available to patients worldwide." "We are grateful to the thousands of patients and investigators worldwide who participated in the ODYSSEY clinical trial program," said Leonard S. Schleifer, M., S. Founder. President, and Chief Executive Officer. Regcneron. "Pralucnt represents the culmination of more than a decade of tireless work to translate the genetic-based discovery of PCSK9 into an innovative medicine that brings meaningful value to patients." Thc approval of Praluent was based on data from the pivotal Phase 3 ODYSSEY program, which showed consistent, positive results compared to placebo, which included current standard of care therapy (statins). In the ODYSSEY LONG TERM trial which evaluated Praluent 150 mg every two weeks. Praluent reduced LDL cholesterol by 58 percent versus placebo at week 24 when added to current standard of care, including maximally tolerated statins. In ODYSSEY COMBO 1, Pralucnt 75 mg every two weeks as an adjunct to statins reduced LDL cholesterol by an additional 46 percent compared to placebo at week 12. At week 24 in the same trial. Praluent reduced LDL cholesterol by 43 percent compared to placebo. In this study, if additional LDL cholesterol lowering was required based on pre-specified criteria at week 8. Praluent was up-titrated to 150 mg at week 12 for the remainder of the trial. Eighty-three percent of patients remained on their initial 75 mg dose. Praluent is generally well-tolerated with an acceptable safety profile. Local injection site reactions including redness, itching, swelling or pain/tenderness where the injection is given were the most common events (7.2 percent with Praluent versus 5.1 percent with placebo) and resulted in a low discontinuation rate that was comparable to placebo (0.2 percent with Praluent versus 0.4 percent with placebo). Patients receiving Praluent had a greater number of injection site reactions, had more reports of associated symptoms. and had reactions of longer average duration than patients receiving placebo. Other common adverse events occurring more frequently in patients with Praluent than placebo included symptoms of the common cold and flu or flu-like symptoms. Thc companies carefully considered the potential medical value that Praluent offers patients in determining the Wholesale Acquisition Cost (WAC). The U.S. WAC price of Praluent is S40 per day (51,120 every 28 days) for both the 75 mg and 150 mg doses, making Praluent the lowest priced patient-administered monoclonal antibody therapy on an annualized basis. Actual costs to patients, payers and health systems are anticipated to be lower as WAC pricing does not re0ect discounts or rebates. Out-of-pocket costs to patients will vary depending on insurance status and eligibility for patient assistance. Sanofi and Regcncron arc committed to ensuring that patients in the U.S. who are prescribed Praluent are able to access the medicine and receive the support they may need. The companies will launch a comprehensive program that offers support. training and follow up for patients at every step of the process. The program will provide patient assistance to uninsured or underinsured patients, including providing free medicine to eligible patients. and can help identify coverage options for out-of-pocket costs. Additional services include educational information, clinical support for physicians, nurses and pharmacists. as well as reimbursement services, including co-pay support for eligible patients and information about insurance eligibility support. For more information, please call I -844-PRALUENT ( I -844-772-5836ca). Earlier today, the companies announced that the European Medicine Agency's (EMA's) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Pralucnt, recommending its approval for use in certain adult patients with hypercholesterolemia. The European Commission (EC) is expected to make a final decision on the Marketing Authorization Application for Praluent in the European Union in September 2015. Investor Relations Conference Call on Praluent Sanofi and Regcncron will be hosting a conference call for the financial community on Praluentit (alirocumab) Injection for
May 7, 2026 at 4:26 AM
epsteinweb.bsky.social
Parts 1-2/2 — EFTA00850478.jpg
#epsteinweb #efta00850478
https://epsteinweb.org
Available in the iOS app store now!
https://apps.apple.com/us/app/epstein-web/id6758880661
EFTA00850478 | EFTA00850478 From: "jeffrcy E." icevacationiragmail.com> To: Sultan Bin Sulayem < > Subject: Re: FDA Approved a Potent and Pricey Cholesterol lowering drug today Date: Fri, 24 Jul 2015 20:47:39 -0000 yes, it requires a shot, its not a pill and so far no long term effects known On Fri, Jul 24, 2015 at 4:37 PM, Sultan Bin Sulaycm Have you heard of this colestrol wrote: Jul 24, 20)5 (a 3:23 PM 1.169 views The FDA Approves A Potent And Pricey Cholesterol-Lowering Shot Herter, Forbes Staff I cover science and medicine, and believe this is biology's century. • Follow on Forbes (1.2210 • • • • • • Full Bio • Recent Posts • Popular Posts I believe this is biology's century. I've covered science and medicine for Forbes from the Human (icnome Project through Vioxx to the blossoming DNA technology changing the world today. Email me, follow me on Twitter, circle me onCioogle Plus, or subscribe to my Facebook page. Loading... Loading... The Food and Drug Administration has approved Praluent. a new medicine to lower cholesterol in people who have established hcan disease, for people whose risk of a heart attack or stroke is not being adequately controlled by existing drugs called satins. It might be a big step in the battle against heart disease - and the approval is a triumph for Regeneron Pharmaceuticals, the Tarrytown,IM -based biotechnology company that invented it. Pralucnt is likely to be more widely used, and to cost more, than Wall Stott analysts expected. That also means it could be a big cost down the line. "Obviously, the class is one of the biggest developments in cardiology in the last decade, that will allow us to treat patients who have been extremely difficult to treat with high levels of LDL cholesterol," says Steven Nissen, chairman of cardiology at the Cleveland Clinic. "It's very promising." But it will also be very expensive, say Troy Brennan, the chief medical officer ofCVS Caremark, the giant pharmacy benefits manager."If these drugs are used as broadly as they could be used, they arc going to be by far the most expensive drug class," Brennan says. Praluent, an injection, lowers low-density lipoprotein, the so-called "bad cholesterol", by as much as 60%, far more than the satin drugs alone. It is the first drug to work by targeting a protein called PCSK9. Mutations in the gene that makes it can result in patients having lower cholesterol and a dramatically lower lifetime risk of heart attacks. A rival medicine from Amgen is also expected to be approved soon. The FDA is clearing Pralucnt for patients with heterozygous familial hypercholesterolemit a genetic condition that causes high cholesterol, and for people who have heart disease, like those who've had hcan attacks or strokes, who are already taking the maximum dose of a satin they can tolerate. Regeneron and its marketing partner Sanofi say Praluent will have a wholesale cost of S40 a day, or $14,600 a year, for either of two doses, 75 milligrams or 150 mgs. It's likely that insurance companies will get a significant discount, because Amgen and Regeneron will compete by giving the insurers rebates. Recommended by Forbes Most Popular Photos: America's New ManufacturingNoomtowm clarreartjuag With A Thrillionaire Flureprencur Most Popular Barrel Rolling With .t Thrall/unity Entrepreneur Most Nadu photos: The 10 Best And Wont States To Make A Liming In 20IS ; I I dTmmp And The Decline Of American Character—A Cautionary Tale Trending on Linkedln Donald Trump And The Decline OrAmerican Character—A Cautionary Tale EFTA00850478
May 7, 2026 at 4:26 AM
pharmacychecker.bsky.social
"The deal involves Regeneron lowering the prices of all its current and future drugs on Medicaid, according to Trump.

It also involves selling a cholesterol drug called Praluent for $225 on the White House’s discounted drug website TrumpRx."

apnews.com/article/trum...
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump has announced a deal with Regeneron to lower the cost of its pharmaceutical products.
apnews.com
April 27, 2026 at 11:07 AM
rantermarkus.bsky.social
TrumpRx Praluent at $225 is cash only and doesn't count toward deductibles. Insured patients already pay $35 to $50 with Regeneron's existing MyPraluent copay card. Medicare and Medicaid patients aren't eligible. The PBM rebate layer underneath is untouched.
April 25, 2026 at 12:57 PM
oldjedimaster.bsky.social
I can get it for $50 with a coupon/card from Regeneron’s website.

Looks like Trump and Regeneron both get to grift under Trump.

Link to discount: www.praluent.com/s/starting-a...
PRALUENT(R) (alirocumab) Injection
See Important Safety Information and Full Prescribing Information. Learn more about PRALUENT(R) (alirocumab) Injection.
www.praluent.com
April 25, 2026 at 12:35 PM
newsweek.com
Regeneron will cut the price of its cholesterol-lowering treatment Praluent to $225, down from $537, on the TrumpRx website.
List of Drugs That Could See Massive Price Cuts Under Trump Deal
www.newsweek.com
April 25, 2026 at 12:31 PM
fujiiponta.bsky.social
The deal involves Regeneron lowering the prices of all its current and future drugs on Medicaid, according to Trump.
It also involves selling a cholesterol drug called Praluent for $225 on the White House’s discounted drug website TrumpRx.
fujiiponta.bsky.social FujiiPonta @fujiiponta.bsky.social · Apr 25
US President Donald Trump on Thursday (April 23) announced a deal with drugmaker Regeneron to lower the cost of its pharmaceutical products as part of the White House’s signature drug pricing initiative.
apnews.com/article/trum...
Trump unveils deal with Regeneron to lower drug prices as part of most-favored-nation initiative
President Donald Trump has announced a deal with Regeneron to lower the cost of its pharmaceutical products.
apnews.com
April 25, 2026 at 5:32 AM
thedeepdive.bsky.social
The Fine Print In Trump’s Most-Favored-Nation Drug Price Deal With Regeneron
Trump’s drug price win comes with missing fine print
Trump says 17 pharma firms now back lower drug prices as Regeneron cuts Praluent to $225 and offers Otarmeni free.
thedeepdive.ca
April 24, 2026 at 5:16 PM
newsweek.com
Regeneron will cut the price of its cholesterol-lowering treatment Praluent to $225, down from $537, on the TrumpRx website.
List of Drugs That Could See Massive Price Cuts Under Trump Deal
www.newsweek.com
April 24, 2026 at 11:31 AM
newsweek.com.web.brid.gy
List of Drugs That Could See Massive Price Cuts Under Trump Deal
Regeneron will cut the price of its cholesterol-lowering treatment Praluent to $225, down from $537, on the TrumpRx website.
www.newsweek.com
April 24, 2026 at 11:38 AM
biblioholic44.bsky.social
“It also involves selling a cholesterol drug called Praluent for $225” Do they think that is affordable? We have patients (on Medicare) who say they can’t afford an $80/month medication. How TF do they think $225 is a good enough price? It didn’t say but I presume this is $225/month.
April 23, 2026 at 11:49 PM
babygoldie.bsky.social
2026-04-24 03:50:15 - Regeneron Pharmaceuticals: Cardiovascular drug Praluent will be sold directly to patients through TrumpRx.
April 23, 2026 at 8:00 PM